- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01858311
Nutrition Blood Outcomes Following Tocotrienol N2B (NIIB)
Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB
A natural form of vitamin E called tocotrienol (TCT) has blood thinning and cholesterol lowering properties, both of which may benefit stroke survivors. This study is being conducted to determine the blood thinning and cholesterol lowering properties of TCT in stroke or TIA (transient ischemic attack, which is also referred to as a "mini-stroke") survivors that are receiving the standard treatment for prevention of recurrent stroke.
Study Hypothesis: Oral TCT decreases the incidence of aspirin and clopidogrel nonresponders, increases the extent of inhibition of platelet aggregation, and decreases LDL without significant side effects in stroke patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
Columbus, Ohio, United States, 43213
- Mount Carmel Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients with either atherothrombotic, cardioembolic, cryptogenic stroke or TIA (transient ischemic attack) for whom anticoagulation is not indicated
- Enrollment in trial must occur within 6 months of clinical presentation for first stroke or TIA event
- No history of long-term vitamin E supplement (defined as daily oral tocopherol or tocotrienol supplementation at least 6mos; within the past 5 years)
- No current vitamin E supplementation in multi-vitamin
Exclusion Criteria:
- Disabling stroke ( Modified Rankin Scale > 3)
- Prior intracranial hemorrhage (excluding traumatic)
- High risk of bleeding (recurrent gastrointestinal, genitourinary bleeding, active peptic ulcer disease)
- Anticipated requirement for long term use of anticoagulation
- Contraindications to antiplatelet agents (bleeding disorder, thrombocytopenia, prolonged INR)
- Irreversible medical condition likely to affect short-term survival or ability to participate in study such as cancer or other chronic disease with predicted survival of less than a year or severe psychiatric or neurologic disease that might complicate evaluation of study outcomes like dementia or schizophrenia
- Pregnancy or women of child bearing age who are not following an effective method of contraception
- Breast feeding
- Unable or unwilling to provide informed
- Unlikely to be compliant with therapy or unwilling to return for follow up frequent clinic visits
- Concurrent participation in another study with an investigational drug or devise
- Other likely specific cause of stroke such as dissection, infectious or noninfectious vasculitis, prothrombotic state
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Placebo vehicle
(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
|
Placebo capsules per day (2 in the morning and 2 in the evening)
|
Tocotrienol capsules (400 mg)
(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
|
Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
|
Tocotrienol Capsules (800 mg)
(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
|
Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
platelet aggregation activity
Time Frame: up to 1 year
|
Platelet aggregation activity will be measured using standard clinical laboratory procedures
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of recurrent stroke
Time Frame: up to 1 year
|
Incidence of recurrent stroke after previous diagnosed stroke or TIA.
|
up to 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Stroke
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Vitamin E
- Tocopherols
- Tocotrienols
Other Study ID Numbers
- 2012H0113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on Placebo Vehicle
-
Galderma R&DCompleted
-
Eisai LimitedCompleted
-
Trefoil Therapeutics, Inc.CompletedEndothelial Dysfunction | Corneal Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Fuchs Endothelial Corneal DystrophyUnited States
-
Celularity IncorporatedCelgene CorporationTerminatedRheumatoid ArthritisUnited States
-
New York Medical CollegeU.S. Army Medical Research and Development Command; Westchester Medical CenterUnknownStress Disorders, Post-Traumatic | Stress Disorders, Traumatic, AcuteUnited States
-
Taro Pharmaceuticals USACompletedPlaque PsoriasisUnited States
-
Integra LifeSciences CorporationIntegriumTerminatedDiabetic Foot UlcersUnited States
-
Raziel Therapeutics Ltd.Completed
-
Taro Pharmaceuticals USACompleted
-
Taro Pharmaceuticals USACompletedOnychomycosisUnited States